BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 113.48 USD 4.85% Market Closed
Market Cap: 27.3B USD
Have any thoughts about
BioNTech SE?
Write Note

Wall Street
Price Targets

BNTX Price Targets Summary
BioNTech SE

Wall Street analysts forecast BNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNTX is 138.68 USD with a low forecast of 100.23 USD and a high forecast of 179.55 USD.

Lowest
Price Target
100.23 USD
12% Downside
Average
Price Target
138.68 USD
22% Upside
Highest
Price Target
179.55 USD
58% Upside

BNTX Last Price Targets
BioNTech SE

The latest public price target was made on Nov 13, 2024 by Daina Graybosch from Leerink Partners , who expects BNTX stock to rise by 7% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Daina Graybosch
Leerink Partners
121 USD
Upside 7%
1 week ago
Nov 13, 2024
BioNTech (BNTX) PT Raised to $121 at Leerink Partners
StreetInsider
Chris Shibutani
Goldman Sachs
137 USD
Upside 21%
2 weeks ago
Nov 8, 2024
Goldman Sachs Upgrades BioNTech (BNTX) to Buy
StreetInsider
Etzer Darout
BMO Capital
126 USD
Upside 11%
2 weeks ago
Nov 4, 2024
BioNTech (BNTX) PT Raised to $126 at BMO Capital
StreetInsider
Terence Flynn
Morgan Stanley
145 USD
Upside 28%
2 months ago
Sep 23, 2024
Morgan Stanley upgrades BioNTech on cancer potential of BNT327
TheFly
Akash Tewari
Jefferies
150 USD
Upside 32%
2 months ago
Sep 17, 2024
Jefferies Upgrades BioNTech (BNTX) to Buy
StreetInsider
Tazeen Ahmad
Bank of America Securities
150 USD
Upside 32%
2 months ago
Sep 16, 2024
BioNTech (BNTX) PT Raised to $150 at BofA Securities
StreetInsider
Akash Tewari
Jefferies
96 USD
Downside 15%
2 months ago
Sep 13, 2024
BioNTech (BNTX) PT Raised to $96 at Jefferies
StreetInsider
Emmanuel Papadakis
Deutsche Bank
95 USD
Downside 16%
3 months ago
Aug 6, 2024
BioNTech upgraded to Buy from Hold at Deutsche Bank
TheFly
Terence Flynn
Morgan Stanley
93 USD
Downside 18%
3 months ago
Aug 5, 2024
BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley
StreetInsider
Yifeng Liu
HSBC
101 USD
Downside 11%
3 months ago
Aug 2, 2024
HSBC Upgrades BioNTech (BNTX) to Buy
StreetInsider
Raghuram Selvaraju
H.C. Wainwright
113 USD
Downside 0%
4 months ago
Jun 26, 2024
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
StreetInsider
Cory Kasimov
Evercore ISI
100 USD
Downside 12%
6 months ago
May 13, 2024
Evercore ISI Starts BioNTech (BNTX) at In Line
StreetInsider
Etzer Darout
BMO Capital
122 USD
Upside 8%
6 months ago
May 7, 2024
BioNTech (BNTX) PT Lowered to $122 at BMO Capital
StreetInsider
Yifeng Liu
HSBC
90 USD
Downside 21%
8 months ago
Mar 22, 2024
BioNTech (BNTX) PT Lowered to $90 at HSBC, 'near-term COVID-19 revenue still remains a risk overhang'
StreetInsider
Chris Shibutani
Goldman Sachs
91 USD
Downside 20%
8 months ago
Mar 21, 2024
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
StreetInsider
William Maughan
Canaccord Genuity
171 USD
Upside 51%
8 months ago
Mar 21, 2024
Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings
StreetInsider
Etzer Darout
BMO Capital
123 USD
Upside 8%
8 months ago
Mar 21, 2024
BioNTech (BNTX) PT Lowered to $123 at BMO Capital
StreetInsider
Unknown Analyst
Goldman Sachs
156 USD
Upside 37%
1 year ago
Jan 31, 2023
Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $156
Benzinga
Show More Price Targets
Show Less Price Targets
Daina Graybosch
Leerink Partners
Price Target 121 USD
Upside/Downside 7%
View Source
Chris Shibutani
Goldman Sachs
Price Target 137 USD
Upside/Downside 21%
View Source
Etzer Darout
BMO Capital
Price Target 126 USD
Upside/Downside 11%
View Source
Terence Flynn
Morgan Stanley
Price Target 145 USD
Upside/Downside 28%
View Source
Akash Tewari
Jefferies
Price Target 150 USD
Upside/Downside 32%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 150 USD
Upside/Downside 32%
View Source
Akash Tewari
Jefferies
Price Target 96 USD
Upside/Downside 15%
View Source
Emmanuel Papadakis
Deutsche Bank
Price Target 95 USD
Upside/Downside 16%
View Source
Terence Flynn
Morgan Stanley
Price Target 93 USD
Upside/Downside 18%
View Source
Yifeng Liu
HSBC
Price Target 101 USD
Upside/Downside 11%
View Source
Raghuram Selvaraju
H.C. Wainwright
Price Target 113 USD
Upside/Downside 0%
View Source
Cory Kasimov
Evercore ISI
Price Target 100 USD
Upside/Downside 12%
View Source
Etzer Darout
BMO Capital
Price Target 122 USD
Upside/Downside 8%
View Source
Yifeng Liu
HSBC
Price Target 90 USD
Upside/Downside 21%
View Source
Chris Shibutani
Goldman Sachs
Price Target 91 USD
Upside/Downside 20%
View Source
William Maughan
Canaccord Genuity
Price Target 171 USD
Upside/Downside 51%
View Source
Etzer Darout
BMO Capital
Price Target 123 USD
Upside/Downside 8%
View Source
Unknown Analyst
Goldman Sachs
Price Target 156 USD
Upside/Downside 37%
View Source
Show More Price Targets
Show Less Price Targets
BioNTech SE Competitors:
Price Targets
STOK
Stoke Therapeutics Inc
99% Upside
TCRX
TScan Therapeutics Inc
202% Upside
87S
Roivant Sciences Ltd
40% Upside
APLT
Applied Therapeutics Inc
40% Upside
ITOS
Iteos Therapeutics Inc
319% Upside
FOLD
Amicus Therapeutics Inc
87% Upside
688235
Beigene Ltd
25% Upside
NTLA
Intellia Therapeutics Inc
323% Upside

Revenue
Forecast

Revenue Estimate
BioNTech SE

For the last 5 years the compound annual growth rate for BioNTech SE's revenue is 97%. The projected CAGR for the next 3 years is -11%.

97%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
0%
Average Beat

Operating Income
Forecast

Operating Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BNTX's stock price target?
Price Target
138.68 USD

According to Wall Street analysts, the average 1-year price target for BNTX is 138.68 USD with a low forecast of 100.23 USD and a high forecast of 179.55 USD.

What is BioNTech SE's Revenue forecast?
Projected CAGR
-11%

For the last 5 years the compound annual growth rate for BioNTech SE's revenue is 97%. The projected CAGR for the next 3 years is -11%.

Back to Top